As of today (2022-05-19), Illumina's share price is $239.81.
Illumina's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 was $1.35. Hence, Illumina's Price-to-Free-Cash-Flow Ratio for today is 177.37.
The historical rank and industry rank for Illumina's Price-to-Free-Cash-Flow or its related term are showing as below:
ILMN'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.31 Med: 55.67 Max: 269.16
Current: 177.39
During the past 13 years, Illumina's highest Price-to-Free-Cash-Flow Ratio was 269.16. The lowest was 13.31. And the median was 55.67.
ILMN's Price-to-Free-Cash-Flow is ranked worse than 94.5% of 109
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.91
vs ILMN: 177.39
During the past 12 months, the average Free Cash Flow per Share Growth Rate of Illumina was -77.60% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -26.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -2.20% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 10.00% per year.
During the past 13 years, Illumina's highest 3-Year average Free Cash Flow per Share Growth Rate was 72.40% per year. The lowest was -26.70% per year. And the median was 17.50% per year.
Illumina Price-to-Free-Cash-Flow Historical Data
The historical data trend for Illumina's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Illumina Annual Data
Trend
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Price-to-Free-Cash-Flow
57.44
52.82
58.70
61.46
170.45
Illumina Quarterly Data
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Price-to-Free-Cash-Flow
63.75
77.73
124.38
170.45
258.43
Competitive Comparison
For the Diagnostics & Research subindustry, Illumina's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina Price-to-Free-Cash-Flow Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Illumina's Price-to-Free-Cash-Flow falls into.
Illumina Price-to-Free-Cash-Flow Calculation
Illumina's Price-to-Free-Cash-Flow ratio for today is calculated as
Illumina's Share Price of today is $239.81.
Illumina's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Illumina Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of Illumina's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates revenue from sequencing tools and dedicated consumables (76% of 2020 sales). Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. Services account for 16% of sales and include basic maintenance services, clinical lab applications (such as noninvasive prenatal, oncology, and rare-disease screening), and whole genome sequencing.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
3.41(1.4%) Volume: 1,657,956 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ILMN has been successfully added to your 
